Lasamide, a Potent Human Carbonic Anhydrase Inhibitor from the Market: Inhibition Profiling and Crystallographic Studies
- PMID: 39411526
- PMCID: PMC11472397
- DOI: 10.1021/acsmedchemlett.4c00341
Lasamide, a Potent Human Carbonic Anhydrase Inhibitor from the Market: Inhibition Profiling and Crystallographic Studies
Abstract
Lasamide is a synthetic precursor and a contaminant of the diuretic Furosemide manufacturing process and represents a highly valuable building block for fragment-based drug discovery approaches. We assessed the ability of Lasamide to inhibit in vitro the human-expressed Carbonic Anhydrases by means of the stopped-flow technique, and we assessed its binding modes within hCAs II and XII-mimic catalytic clefts by X-ray crystallography. Interestingly, an unprecedented crystal form for the hCA IX mimic H-tag is reported and discussed herein.
© 2024 American Chemical Society.
Conflict of interest statement
The authors declare no competing financial interest.
References
-
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans . Pharmaceutical Drugs; International Agency for Research on Cancer: Lyon (FR), 1990.
-
- Temperini C.; Cecchi A.; Scozzafava A.; Supuran C. T. Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg. Med. Chem. 2009, 17 (3), 1214–1221. 10.1016/j.bmc.2008.12.023. - DOI - PubMed
-
- Liu F.; Martin-Mingot A.; Lecornué F.; Jouannetaud M. P.; Maresca A.; Thibaudeau S.; Supuran C. T. Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry. J. Enzyme Inhib. Med. Chem. 2012, 27 (6), 886–891. 10.3109/14756366.2011.638921. - DOI - PubMed
-
- Farzam K.; Abdullah M.. Acetazolamide. StatPearls. StatPearls Publishing: Treasure Island (FL), 2024. - PubMed